Project Details
Projekt
Harnessing Metabolic Modulation of Tregs and Dendritic Cells to Enhance Immunotherapy Efficacy (18)
Subject Area
Immunology
Term
since 2020
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 318346496
Cancer immune evasion limits ICB therapy, with Treg expansion contributing to resistance and tumor growth. Tregs also suppress immunity in chronic infections like tuberculosis. We discovered a bacterial peptide which inhibits Treg differentiation, reduces tumor burden in mice, and shows potential for cancer and infection therapy. Its molecular mechanism is independent of Foxm1, possibly acting via proteasomal or mitochondrial pathways. Combining this compound with Batf3-DC recruitment strategies may enhance ICB efficacy. Future work aims to optimize derivatives for safety and solubility.
DFG Programme
Collaborative Research Centres
Subproject of
SFB 1292:
Targeting convergent mechanisms of inefficient immunity in tumors and chronic infections
Applicant Institution
Johannes Gutenberg-Universität Mainz
